But with Brukinsa and degraders looming, will fixed dosing make the difference?

Etentamig is one of several anti-BCMA T-cell engagers seeking attention at ASH.

Phase 2 data show why Merck took the lowest dose of zilo-V into phase 3.

The group presents data with bleximenib plus chemo, but looks behind Kura’s contender.

Enzomenib might be the most promising agent so far, on a cross-trial basis.

JNJ-89853413 is disclosed as the lead in the two companies' 2020 alliance.

In first-line NSCLC the drug beats chemo, and not Keytruda.

And the company might one day follow Galapagos into decentralised manufacturing.

The Aquila study could make Darzalex the first approved drug for smouldering multiple myeloma.